IntroductionIn this study, we aimed to focus on reduced expression of E-cadherin (CDH1) and its prognostic value in pancreatic cancer (PC) using a meta-analysis.Material and methodsFor this purpose, the PubMed and EMBASE databases were searched from inception until September 1, 2018. Hazard ratio (HR) and 95% confidence interval (CI) were pooled to evaluate the association between CDH1 expression and overall survival (OS); also, odds ratio (OR) and 95% CI were used to assess the correlation between clinicopathological features and CDH1 expression in PC patients. Data from a total of 1805 patients from 16 articles were used in this meta-analysis.ResultsPC patients with decreased expression of CDH1 had a shorter OS (HR = 1.25, 95% CI: 1.09–1.41), without a significant heterogeneity (I2 = 27.1%, p = 0.151). The down-regulated expression of CDH1 was strongly associated with tumour grade (OR = 1.80, 95% CI: 1.07–3.03).ConclusionsDown-regulated expression of CDH1 has potential as a predictive marker of poor prognosis in PC patients. However, further high-quality and large-scale clinical studies are required to validate our findings.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.